myeloid cells

[Signal Transduction and Targeted Therapy] Scientists discuss the latest developments in the immunopathological characteristics of COVID-19 and focus on cytokine storm including the current research status of the different cytokines involved.

[Genome Biology] Using scRNA-Seq analysis of chimeric mouse embryos lacking the major erythroid regulator Gata1, scientists showed that genes with the step-changes in expression dynamics during erythroid differentiation failed to be upregulated in the mutant cells, thus underscoring the coordination of modulating transcription rate along a differentiation trajectory.

[Nature Communications] Investigators showed that GM-CSF produced by cord blood-derived inflammatory monocytes drove pre-engraftment syndrome pathology (PES), and that monocytes were the main source of IL-6 during PES. They also reported the outcome of a clinical study of tocilizumab in the treatment of steroid-refractory severe PES patients.

[Trillium Therapeutics, Inc.] Trillium Therapeutics, Inc. announced that it has dosed the first acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and venetoclax.

[Cell Reports] The authors investigated mutant HTT-associated changes in gene expression by mouse and human striatal astrocytes, as well as in mouse microglia, to identify commonalities in glial pathobiology across species and models.

[Cell Death & Differentiation] When comparing nasopharyngeal swabs from cancer and noncancer patients for RT-qPCR cycle thresholds measuring acute respiratory SARS-CoV-2 in 1063 patients, researchers found that malignant disease favored the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies.